Novartis drug Exjade® approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia »

[at noodls] – Exjade is the first oral treatment approved in the EU for chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes Pivotal placebo-controlled study data show Exjade … more

View todays social media effects on NVS

View the latest stocks trending across Twitter. Click to view dashboard

See who Novartis is hiring next, click here to view